Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a clinically confirmed diagnosis of active Atopic Dermatitis according to Hanifin and Rajka criteria~* Patients with mild to moderate Atopic Dermatitis at baseline as defined by an Investigator's Global Assessment (IGA) score of 3 or 2 at baseline visit~* Patients with Atopic Dermatitis covering a minimum 5% of the body surface area at baseline~* Male or female patients aged 18 years and older on the day of signing the informed consent form (ICF)~Exclusion Criteria:~* Patients with other skin conditions that might interfere with Atopic Dermatitis diagnosis and/or evaluation (such as psoriasis or current active viral, bacterial and fungal topical skin infections) as assessed by the Investigator~* Patients who have used systemic treatments (other than biologics) that could affect Atopic Dermatitis less that 4 weeks prior to baseline visit (Day 0), e.g. retinoids, methotrexate, cyclosporine, hydroxycarbamide (hydroxyurea), azathioprine and oral/injectable corticosteroids. Intranasal corticosteroids for stable medical conditions are allowed~* Patients who have used any topical medicated treatment for Atopic Dermatitis two weeks prior to the start of treatment/baseline (Day 0) including but not limited to, topical corticosteroids, calcineurin inhibitors, tars, bleach, antimicrobials, and bleach baths~* Patients who use topical products containing urea, ceramides or hyaluronic acid two weeks prior to Day 0~* Patients who have a history of hypersensitivity to any substance in DS107 cream or vehicle cream~* Patients who have any clinically significant controlled or uncontrolled medical condition or laboratory abnormality that would, in the opinion of the Investigator, put the patient at undue risk or interfere with the interpretation of study results~* Patients with significant uncontrolled cardiovascular, neurologic, malignant, psychiatric, respiratory or hypertensive disease, as well as uncontrolled diabetes and floride arthritis or any other illness that, in the opinion of the Investigator, is likely to interfere with completion of the study~* Patients with chronic infectious diseases (e.g. hepatitis B, hepatitis C, or infection with human immunodeficiency virus)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vehicle Cream (Type: PLACEBO_COMPARATOR): Vehicle cream applied topically to all affected or commonly affected areas twice-daily for 8 weeks
- 1% DS107 Cream (Type: EXPERIMENTAL): 1% DS107 cream applied topically to all affected or commonly affected areas twice-daily for 8 weeks
- 5% DS107 Cream (Type: EXPERIMENTAL): 5% DS107 cream applied topically to all affected or commonly affected areas twice-daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete